- call +1-201-465-4211
- email sales@mrinsights.biz
According to this latest study, the 2021 growth of Benign Prostatic Hyperplasia (BPH) Drugs will have significant change from previous year. By the most conservative estimates of global Benign Prostatic Hyperplasia (BPH) Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 3222.4 million in 2020. Over the next five years the Benign Prostatic Hyperplasia (BPH) Drugs market will register a 0.9% CAGR in terms of revenue, the global market size will reach US$ 3344.4 million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2016-2026
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2016-2021)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2016-2021)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Drugstores
2.4.3 Others
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2016-2021)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Application (2016-2021)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2016-2021)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Company
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2019-2021)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2019-2021)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2019-2021)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2019-2021)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company
3.4 Global Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Location Distribution
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Benign Prostatic Hyperplasia (BPH) Drugs by Region
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs by Region
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
5 Americas
5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer
11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Region
11.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions (2021-2026)
11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type
11.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application
12 Key Players Analysis
12.1 Eli Lilly
12.1.1 Eli Lilly Company Information
12.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Eli Lilly Main Business Overview
12.1.5 Eli Lilly Latest Developments
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Company Information
12.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 GlaxoSmithKline Main Business Overview
12.2.5 GlaxoSmithKline Latest Developments
12.3 Astellas Pharma
12.3.1 Astellas Pharma Company Information
12.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Astellas Pharma Main Business Overview
12.3.5 Astellas Pharma Latest Developments
12.4 Sanofi
12.4.1 Sanofi Company Information
12.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Sanofi Main Business Overview
12.4.5 Sanofi Latest Developments
12.5 Pfizer
12.5.1 Pfizer Company Information
12.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Pfizer Main Business Overview
12.5.5 Pfizer Latest Developments
12.6 Abbott
12.6.1 Abbott Company Information
12.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Abbott Main Business Overview
12.6.5 Abbott Latest Developments
12.7 Allergan
12.7.1 Allergan Company Information
12.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Allergan Main Business Overview
12.7.5 Allergan Latest Developments
12.8 TEVA
12.8.1 TEVA Company Information
12.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 TEVA Main Business Overview
12.8.5 TEVA Latest Developments
12.9 Mylan
12.9.1 Mylan Company Information
12.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Mylan Main Business Overview
12.9.5 Mylan Latest Developments
12.10 Novartis
12.10.1 Novartis Company Information
12.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 Novartis Main Business Overview
12.10.5 Novartis Latest Developments
12.11 Merck
12.11.1 Merck Company Information
12.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.11.4 Merck Main Business Overview
12.11.5 Merck Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Alpha-Blocker
Table 3. Major Players of Phosphodiesterase Type-5 Inhibitors
Table 4. Major Players of Others
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & ($ million)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2016-2021)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Application (2016-2021)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2016-2021)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2019-2021) & (M Units)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2019-2021)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2019-2021) ($ Millions)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2019-2021)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2019-2021)
Table 20. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution and Sales Area
Table 21. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
Table 22. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) (M Units)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Table 29. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 30. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 31. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 32. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 33. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 37. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 38. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 39. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 40. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Table 41. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)
Table 58. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 59. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)
Table 60. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 61. Key and Potential Regions of Benign Prostatic Hyperplasia (BPH) Drugs
Table 62. Key Application and Potential Industries of Benign Prostatic Hyperplasia (BPH) Drugs
Table 63. Key Challenges of Benign Prostatic Hyperplasia (BPH) Drugs
Table 64. Key Trends of Benign Prostatic Hyperplasia (BPH) Drugs
Table 65. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 66. Benign Prostatic Hyperplasia (BPH) Drugs Customer List
Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2021-2026) & (M Units)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Forecast by Region
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2021-2026) & ($ millions)
Table 70. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2021-2026)
Table 71. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2021-2026) & (M Units)
Table 72. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2021-2026) & ($ millions)
Table 73. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2021-2026) & (M Units)
Table 74. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2021-2026) & ($ millions)
Table 75. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2021-2026) & (M Units)
Table 76. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2021-2026) & ($ millions)
Table 77. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2021-2026) & (M Units)
Table 78. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2021-2026) & ($ millions)
Table 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2021-2026) & (M Units)
Table 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2021-2026)
Table 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2021-2026)
Table 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2021-2026) & (M Units)
Table 84. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2021-2026)
Table 85. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 86. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 87. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 89. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 90. Eli Lilly Main Business
Table 91. Eli Lilly Latest Developments
Table 92. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 94. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 95. GlaxoSmithKline Main Business
Table 96. GlaxoSmithKline Latest Developments
Table 97. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 99. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 100. Astellas Pharma Main Business
Table 101. Astellas Pharma Latest Developments
Table 102. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 104. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 105. Sanofi Main Business
Table 106. Sanofi Latest Developments
Table 107. Pfizer Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 109. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 110. Pfizer Main Business
Table 111. Pfizer Latest Developments
Table 112. Abbott Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 114. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 115. Abbott Main Business
Table 116. Abbott Latest Developments
Table 117. Allergan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 119. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 120. Allergan Main Business
Table 121. Allergan Latest Developments
Table 122. TEVA Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 124. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 125. TEVA Main Business
Table 126. TEVA Latest Developments
Table 127. Mylan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 129. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 130. Mylan Main Business
Table 131. Mylan Latest Developments
Table 132. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 134. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 135. Novartis Main Business
Table 136. Novartis Latest Developments
Table 137. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 139. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 140. Merck Main Business
Table 141. Merck Latest Developments
List of Figures
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2026 (M Units)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Alpha-Blocker
Figure 10. Product Picture of Phosphodiesterase Type-5 Inhibitors
Figure 11. Product Picture of Others
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2016-2021) & (M Units)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2016-2021) & (M Units)
Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2016-2021) & (M Units)
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2020
Figure 22. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market by Company in 2020 ($ Million)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2020
Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2016-2021)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2020
Figure 26. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)
Figure 27. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)
Figure 28. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)
Figure 29. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)
Figure 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)
Figure 31. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)
Figure 32. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)
Figure 33. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)
Figure 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 38. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 39. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
Figure 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2020
Figure 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 45. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 46. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 47. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 48. Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 49. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 50. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 51. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 54. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 56. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 57. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 58. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 59. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 60. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 61. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 62. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020
Figure 63. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020
Figure 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020
Figure 65. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 66. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 67. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 68. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 69. GCC Country Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
